

=> d his

(FILE 'HOME' ENTERED AT 09:34:53 ON 10 MAR 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:35:04 ON 10 MAR 2003

E BETAIN/CN
L1 1 S E3
L2 3 S C5H12NO2/MF AND N N N TRIMETHYL AND CARBOX? AND METHANAMIN?
L3 1 S L2 NOT (LABELED OR D/ELS)
L4 2 S L1,L3
E SILIBIN/CN
L5 1 S E4
E SILYMARIN/CN
L6 7 S E3,E6,E8,E9,E10,E13,E15
L7 6 S L6 NOT C4H6O4
L8 6 S L5,L7
L9 3 S (D-GLUCOSE OR L-GLUCOSE OR DL-GLUCOSE)/CN
L10 14 S (D-FRUCTOSE OR L-FRUCTOSE OR DL-FRUCTOSE OR D-GALACTOSE OR L-
L11 8 S (GLYCEROL OR LIPOIC ACID OR CITRIC ACID OR PHOSPHORIC ACID OR
L12 3 S (D-METHIONINE OR L-METHIONINE OR DL-METHIONINE)/CN
L13 1 S TOCOPHEROL/CN
L14 1 S VITAMIN E/CN
L15 9 S (SODIUM OR POTASSIUM OR CHLORINE OR PHOSPHORUS OR MAGNESIUM O
E SODIUM, ION/CN
L16 2 S E4,E170
E POTASSIUM, ION/CN
L17 2 S E6,E108
E CHLORINE, ION/CN
L18 4 S E9,E11,E20,E21
E PHOSPHORUS, ION/CN
L19 2 S E4,E25
E MAGNESIUM, ION/CN
L20 2 S E4,E29
E ZINC, ION/CN
L21 2 S E6,E19
E CALCIUM, ION/CN
L22 2 S E10,E23
E IRON, ION/CN
L23 2 S E6,E43
E COPPER, ION/CN
L24 2 S E7,E55

FILE 'HCAPLUS' ENTERED AT 09:49:25 ON 10 MAR 2003

L25 4700 S L4 OR L8
E SILYMARIN
L26 637 S E3-E5,E8
L27 0 S SILY MARIN?
L28 15024 S BETAIN
L29 115 S FLAVONOLIGNAN?
E LIGNANS/CT
L30 42 S E4
E E3+ALL
L31 2724 S E2+NT
L32 320 S LIGNAN(L) FLAVON?
L33 19242 S L25-L32
L34 794 S L33 AND CARBOHYDRATE?/SC, SX, CW, BI
L35 316 S L33 AND (?OLIGOSACCHARIDE? OR ?POLYSACCHARIDE?)
L36 399 S L33 AND ?SACCHARIDE?
L37 324 S L33 AND L9
L38 627 S L33 AND GLUCOSE
L39 322 S L33 AND L10
L40 483 S L33 AND (FRUCTOSE OR GALACTOSE OR MANNOSE OR RIBOSE OR INOSIT

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CNC 1507 - 703-308-4498
jan.delaval@usprio.gov

L41 1795 S L34-L40
 L42 359 S L41 AND L11
 L43 90 S L41 AND L12
 L44 43 S L41 AND L13,L14
 L45 651 S L41 AND (GLYCEROL OR GLYCERIN# OR LIPOIE ACID OR CITRATE OR P
 L46 687 S L42-L45
 L47 96 S L46 AND L15-L24
 L48 46 S L46 AND MINERAL
 L49 450 S L46 AND (NA OR K OR CL OR P OR MG OR ZN OR CA OR FE OR CU OR
 L50 454 S L47-L49
 SAV L50 KWON770/A

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:14:56 ON 10 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Mar 2003 VOL 138 ISS 11

FILE LAST UPDATED: 9 Mar 2003 (20030309/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l114 all hitstr tot

L114 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:574972 HCAPLUS

DN 137:124619

TI **Rehydration** compositions containing electrolytes and nutrients

IN **Hageman, Robert Johan Joseph; Verlaan, George; Smeets, Rudolf Leonardus Lodewijk**

PA **Nutricia N.V., Neth.**

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61P001-12

ICS A61K031-70; A61K031-35

CC 18-7 (Animal **Nutrition**)

Section cross-reference(s):.63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058792	A2	20020801	WO 2002-NL63	20020128
	WO 2002058792	A3	20021121		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002176881 A1 20021128 US 2001-770773 20010126

PRAI US 2001-770773 A 20010126

- AB The invention relates to a fluid that can be used for preventing or treating **hypohydration** and the secondary consequences thereof. The fluid comprises one or more **carbohydrates** and **minerals** and is further characterized by a low osmolarity. The invention further relates to the use of such a fluid for medical, dietetic and other applications. A **sportsdrink** contained **glucose** 8, **fructose** 6, maltodextrin 20, **glycerol** 1, **taurine** 1, **betaine** 1, caffeine 0.1, **sodium phosphate** 0.5, **sodium chloride** 0.1, and **potassium citrate** 0.3 g per serving 567 mL.
- ST rehydration drink **saccharide** electrolyte **betaine** nutrient
- IT Cardiovascular system
 (disease; **rehydration drinks** contg. electrolytes and nutrients)
- IT Dairy products
 (drinks; **rehydration drinks** contg. electrolytes and nutrients)
- IT Aging, animal
 (elderly; **rehydration drinks** contg. electrolytes and nutrients)
- IT Drug delivery systems
 (enteric; **rehydration drinks** contg. electrolytes and nutrients)
- IT Lignans
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (flavonolignans; **rehydration drinks** contg. electrolytes and nutrients)
- IT Beverages
 Cystic fibrosis
 Dehydration, physiological
 Diarrhea
 Exercise
 Fruit and vegetable juices
 Guarana (Paullinia cupana)
 Intestine, disease
 (rehydration drinks contg. electrolytes and nutrients)
- IT Betaines
 Carbohydrates, biological studies
 Monosaccharides
 Oligosaccharides, biological studies
 Polysaccharides, biological studies
 Tocopherols
 Vitamins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (rehydration drinks contg. electrolytes and nutrients)
- IT Hydration, physiological
 (rehydration; **rehydration drinks** contg. electrolytes and nutrients)
- IT 50-69-1, D-Ribose 50-99-7, D-Glucose
 , biological studies 56-81-5, **Glycerol**, biological

studies 57-48-7, D-Fructose, biological studies
 58-08-2, Caffeine, biological studies 59-23-4, D-
 Galactose, biological studies 63-68-3, L-
 Methionine, biological studies 77-92-9, Citric
 acid, biological studies 87-89-8, Inositol
 107-35-7, Taurine 869-06-7, Magnesium
 malate 3458-28-4, D-Mannose 6915-15-7
 , Malic acid 7632-05-5, Sodium phosphate
 7647-14-5, Sodium chloride, biological studies 7664-38-2
 , Phosphoric acid, biological studies 7778-49-6,
 Potassium citrate 9050-36-6, Maltodextrin
 17482-42-7, Calcium malate 22888-70-6
 57828-26-9, Lipoic acid 65666-07-1, Silymarin
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)


(rehydration drinks contg. electrolytes and
 nutrients)

IT 50-69-1, D-Ribose 50-99-7, D-Glucose
 , biological studies 56-81-5, Glycerol, biological
 studies 57-48-7, D-Fructose, biological studies
 58-08-2, Caffeine, biological studies 59-23-4, D-
 Galactose, biological studies 63-68-3, L-
 Methionine, biological studies 77-92-9, Citric
 acid, biological studies 87-89-8, Inositol
 107-35-7, Taurine 3458-28-4, D-Mannose
 6915-15-7, Malic acid 7664-38-2, Phosphoric
 acid, biological studies 22888-70-6 57828-26-9
 , Lipoic acid 65666-07-1, Silymarin
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)

(rehydration drinks contg. electrolytes and
 nutrients)


RN 50-69-1 HCAPLUS
 CN D-Ribose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-99-7 HCAPLUS
 CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 56-81-5 HCAPLUS
 CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)




RN 57-48-7 HCAPLUS
CN D-Fructose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-08-2 HCAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9CI) (CA INDEX NAME)




RN 59-23-4 HCAPLUS
CN D-Galactose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 63-68-3 HCAPLUS
CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77-92-9 HCAPLUS
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 87-89-8 HCAPLUS
CN myo-Inositol (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 107-35-7 HCAPLUS
CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)




RN 3458-28-4 HCAPLUS
CN D-Mannose (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 6915-15-7 HCAPLUS
CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)




RN 7664-38-2 HCAPLUS
CN Phosphoric acid (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 22888-70-6 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 2-[(2R,3R)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 57828-26-9 HCAPLUS
 CN Lipoic acid (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 65666-07-1 HCAPLUS
 CN Silymarin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:465733 HCAPLUS

DN 137:37656

TI Health promoting composition containing vitamins

IN Clayton, Paul

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A23L001-30

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047493	A2	20020620	WO 2001-EP14260	20011205
	WO 2002047493	A3	20021017		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1214893	A1	20020619	EP 2000-127644	20001216
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	DE 10109798	A1	20020912	DE 2001-10109798	20010301
	AU 2002021934	A5	20020624	AU 2002-21934	20011205
PRAI	EP 2000-127644	A	20001216		
	DE 2001-10109798	A	20010301		

WO 2001-EP14260 W 20011205

- AB The invention refers to several compns. promoting human **health** comprising one or several but no all of the following compds. a) 800 mcg (2664IU) of **vitamin A**, 500 mg of **vitamin C**, 15 mcg of **vitamin D**, 265 mg (400IU) of **vitamin E**, 50 mcg of **vitamin K**, b) 10 mg of .beta.-carotene, 6 mg of lutein, 5mg of lycopene, 100 mcg of zeaxanthin, c) 7.5 mg of **vitamin B1**, 7.5 mg of **vitamin B2**, 15 mg of niacin, 15 mg of pantothenic acid, 7.5 mg of **vitamin B6**, 200 mcg of folic acid, 6.75 mcg of **vitamin B12**, d) 150 mcg of selenium, 10 mg of zinc, 100 mg of calcium, 50 mg of magnesium, 120 mcg of chromium, 2 mg of copper, 4 mg of manganese, 100 mcg of iodine, 100 mcg of molybdenum, e) 200 mcg of biotin, 450 mg of **betaine**, 100 mg of oligoproanthocyanidins (OPC), 150 mg of Polyphenol complex, 40 mg of Isoflavones in particular genistein and/or daidzein, 600 mg of Omega 3, 4 g of **Oligosaccharides** (FOS) in particular inulin, and/or oligo-fructose and/or beta glucan, 30-60 mg of Co-Q10, f) 500 mg of glucosamine and possibly addnl. substances for the purpose of stabilization and formulation.
- ST **health promoting compn vitamin**
- IT Antiasthmatics
Antidiabetic agents
Mental disorder
(**health promoting compn. contg. vitamins**)
- IT **Oligosaccharides**, biological studies
Vitamins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**health promoting compn. contg. vitamins**)
- IT Flavones
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(isoflavones; **health promoting compn. contg. vitamins**)
- IT Proanthocyanidins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; **health promoting compn. contg. vitamins**)
- IT Phenols, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyphenols, nonpolymeric; **health promoting compn. contg. vitamins**)
- IT Fatty acids, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; **health promoting compn. contg. vitamins**)
- IT Fatty acids, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-6; **health promoting compn. contg. vitamins**)
- IT Diet
(supplements; **health promoting compn. contg. vitamins**)
- IT 50-81-7, **Vitamin c**, biological studies 58-85-5, Biotin
59-30-3, Folic acid, biological studies 59-43-8, **Vitamin b1**, biological studies 59-67-6, Niacin, biological studies 68-19-9, **Vitamin b12**

79-83-4, Pantothenic acid 83-88-5, Vitamin b2, biological studies 107-43-7, Betaine 127-40-2, Lutein 144-68-3, Zeaxanthin 303-98-0, Coenzyme q10 446-72-0, Genistein 486-66-8, Daidzein 502-65-8, Lycopene 1406-18-4, Vitamin e 3416-24-8, D-Glucosamine 7235-40-7, .beta.-Carotene 7439-96-5, Manganese, biological studies 7439-98-7, Molybdenum, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7553-56-2, Iodine, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin b6 9041-22-9, .beta.-Glucan 11103-57-4, Vitamin a 12001-79-5, Vitamin k 25702-76-5, Polyfructose
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(health promoting compn. contg. vitamins)

IT 50-81-7, Vitamin c, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Vitamin b1, biological studies 59-67-6, Niacin, biological studies 68-19-9, Vitamin b12 79-83-4, Pantothenic acid 83-88-5, Vitamin b2, biological studies 107-43-7, Betaine 127-40-2, Lutein 144-68-3, Zeaxanthin 303-98-0, Coenzyme q10 446-72-0, Genistein 486-66-8, Daidzein 502-65-8, Lycopene 1406-18-4, Vitamin e 3416-24-8, D-Glucosamine 7235-40-7, .beta.-Carotene 7439-96-5, Manganese, biological studies 7439-98-7, Molybdenum, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7553-56-2, Iodine, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin b6 9041-22-9, .beta.-Glucan 11103-57-4, Vitamin a 12001-79-5, Vitamin k 25702-76-5, Polyfructose
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(health promoting compn. contg. vitamins)

IT 50-81-7, Vitamin c, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Vitamin b1, biological studies 59-67-6, Niacin, biological studies 68-19-9, Vitamin b12 79-83-4, Pantothenic acid 83-88-5, Vitamin b2, biological studies 107-43-7, Betaine 1406-18-4, Vitamin e 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 8059-24-3, Vitamin b6 11103-57-4, Vitamin a 12001-79-5, Vitamin k
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(health promoting compn. contg. vitamins)

RN 50-81-7 HCAPLUS
 CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3. HCAPLUS


CN L-Glutamic acid, N-[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)

● Cl⁻

RN 59-67-6 HCAPLUS


CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 68-19-9 HCAPLUS

CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 79-83-4 HCAPLUS
 CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 83-88-5 HCAPLUS
 CN Riboflavin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107-43-7 HCAPLUS
 CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1406-18-4 HCAPLUS
 CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7440-50-8 HCAPLUS
 CN Copper (7CI, 8CI, 9CI) (CA INDEX NAME)

Cu

RN 7440-66-6 HCAPLUS
 CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 8059-24-3 HCAPLUS
 CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11103-57-4 HCAPLUS
 CN Vitamin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 12001-79-5 HCAPLUS

CN Vitamin K (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:462447 HCAPLUS

DN 137:11020

TI Health promoting compositions

IN Clayton, Paul

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A23L001-30

ICS A61K035-78

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 18

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1214893	A1	20020619	EP 2000-127644	20001216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2002047493	A2	20020620	WO 2001-EP14260	20011205
	WO 2002047493	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002021934	A5	20020624	AU 2002-21934	20011205
	US 2002146463	A1	20021010	US 2001-14488	20011214
PRAI	EP 2000-127644	A	20001216		
	DE 2001-10109798	A	20010301		
	WO 2001-EP14260	W	20011205		
AB	The invention refers to several compns. promoting human health comprising one or several but not all of the following compds.: (a) 800 mcg (2664 IU) of vitamin A, 500 mg of vitamin C, 15 mcg of vitamin D, 265 mg (400 IU) of vitamin E, 50 mcg of vitamin K, (b) 10 mg of .beta.-carotene, 6 mg of lutein, 5 mg of lycopene, 100 mcg of zeaxanthin, (c) 7.5 mg of vitamin B1, 7.5 mg of vitamin B2, 15 mg of niacin, 15 mg of pantothenic acid, 7.5 mg of vitamin B6, 200 mcg of folic acid, 6.75 mcg of vitamin B12, (d) 150 mcg of selenium, 10 mg of Zn, 100 mg of Ca, 50 mg of Mg, 120 mcg of Cr, 2 mg of Cu, 4 mg of Mn, 100 mcg of I, 100 mcg of molybdenum, (e) 200 mcg of biotin, 450 mg of betaine, 100 mg of oligoproanthocyanidins, 150 mg of polyphenol complex, 40 mg of isoflavones in particular genistein and/or daidzein, 600 mg of omega 3 and 6, 4 g of oligosaccharides in particular inulin, and/or oligo-fructose and/or beta glucan, 30-60 mg of Co-Q10, (f) 500 mg of glucosamine, and				

possibly substances for the purpose of stabilization and formulation.

ST **health** promoting compn **vitamin** trace element

IT **Oligosaccharides**, biological studies

Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**health** promoting compns. contg.)

IT Drug delivery systems

(**health** promoting compns. in)

IT Proanthocyanidins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oligo-; **health** promoting compns. contg.)

IT Phenols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyphenols, nonpolymeric; **health** promoting compns. contg.)

IT 50-81-7, **Vitamin C**, biological studies 57-48-7D
 , **Fructose**, oligo- 58-85-5, **Biotin** 59-30-3, **Folic acid**, biological studies 59-43-8, **Vitamin B1**,
 biological studies 59-67-6, **Niacin**, biological studies
 68-19-9, **Vitamin B12** 83-88-5, **Vitamin B2**, biological studies 107-43-7, **Betaine** 127-40-2,
Lutein 144-68-3, **Zeaxanthin** 486-66-8, **Daidzein** 502-65-8, **Lycopene**
 1406-16-2, **Vitamin D** 1406-18-4,
Vitamin E 7235-40-7, **.beta.-Carotene** 7439-95-4
 , **Magnesium**, biological studies 7439-96-5, **Manganese**,
 biological studies 7439-98-7, **Molybdenum**, biological studies
 7440-47-3, **Chromium**, biological studies 7440-50-8,
Copper, biological studies 7440-66-6, **Zinc**,
 biological studies 7440-70-2, **Calcium**, biological
 studies 7553-56-2, **Iodine**, biological studies 7782-49-2, **Selenium**,
 biological studies 8059-24-3, **Vitamin B6** 9005-80-5,
Inulin 9041-22-9, **.beta.-Glucan** 11103-57-4, **Vitamin A** 12001-79-5, **Vitamin K**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**health** promoting compns. contg.)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Kosbab, J; WO 9833494 A 1998 HCAPLUS

(2) Melegari, P; WO 0053176 A 2000 HCAPLUS

(3) Rodney, C; WO 9900135 A 1999 HCAPLUS

(4) Walsh Leo; US 6139872 A 2000 HCAPLUS

IT 50-81-7, **Vitamin C**, biological studies 57-48-7D
 , **Fructose**, oligo- 59-30-3, **Folic acid**, biological
 studies 59-43-8, **Vitamin B1**, biological studies
 59-67-6, **Niacin**, biological studies 68-19-9,
Vitamin B12 83-88-5, **Vitamin B2**, biological
 studies 107-43-7, **Betaine** 1406-16-2,
Vitamin D 1406-18-4, **Vitamin E**
 7439-95-4, **Magnesium**, biological studies
 7440-50-8, **Copper**, biological studies 7440-66-6
 , **Zinc**, biological studies 7440-70-2, **Calcium**
 , biological studies 8059-24-3, **Vitamin B6**
 11103-57-4, **Vitamin A** 12001-79-5,
Vitamin K


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**health** promoting compns. contg.)

RN 50-81-7 HCAPLUS


CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-48-7 HCAPLUS
 CN D-Fructose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-30-3 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS
 CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)




Cl⁻

RN 59-67-6 HCAPLUS
 CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 68-19-9 HCAPLUS
 CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 83-88-5 HCAPLUS
 CN Riboflavin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107-43-7 HCAPLUS
 CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1406-16-2 HCAPLUS
 CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1406-18-4 HCAPLUS
 CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-50-8 HCAPLUS

CN Copper (7CI, 8CI, 9CI) (CA INDEX NAME)

Cu

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 8059-24-3 HCAPLUS

CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11103-57-4 HCAPLUS

CN Vitamin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 12001-79-5 HCAPLUS

CN Vitamin K (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:271056 HCAPLUS

DN 136:299719

TI **Dietary** supplement for promoting **healthy** hormonal balance

IN Hastings, Carl W.; Barnes, David J.; Daley, Christine A.

PA Reliv' International, Inc., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-14

ICS A61K047-28; A61K031-56

NCL 424439000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 18

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6368617	B1	<u>20020409</u>	US 2001-858047	<u>20010515</u>
PRAI	US 2001-858047		<u>20010515</u>		

- AB A dietary supplement for promoting **healthy** hormonal balance in adult human subjects, and esp. in elderly subjects, comprises a secretagogue for stimulating the release of human growth hormone (hGH) by the pituitary, and the conversion by hGH to insulin-like growth factor 1 (IGF-1), in combination with 7-keto-dehydroepiandrosterone (7-keto DHEA). The dietary supplement also includes other interacting ingredients for delivering antioxidants for retarding damage at the cellular level caused by the presence of free radicals, and natural herbs for promoting physiol. **health**. For example, an essentially dry powder constituting a dietary supplement of this invention, to be dissolved in water to provide a daily serving, contained 7-keto-DHEA 25 **mg**, Symbiotropin 1000 **mg**, lecithin 200 **mg**, maltodextrin 7.227 **mg**, citric acid 640 **mg**, dipotassium phosphate 25 **mg**, potassium citrate 25 **mg**, probiotic blend 100 **mg**, fructooligosaccharides 400 **mg**, S-adenosyl-L-methionine 5 **mg**, acetyl-L-carnitine 100 **mg**, omega-3 fatty acids (Dry n-3) 125 **mg**, trimethylglycine 100 **mg**, coenzyme Q10 7.5 **mg**, resveratrol (Prottykin) 10 **mg**, .alpha.-lipoic acid 50 **mg**, L-glutathione 30 **mg**, N-acetylcysteine 200 **mg**, and flavoring agents 300 **mg**.
- ST ketodehydroepiandrosterone growth hormone secretagogue oral dietary supplement aging
- IT Aging, animal
Antioxidants
Beverages
Bifidobacterium bifidum
Ginkgo
Human
Lactobacillus acidophilus
Spirulina
Spirulina platensis
Yam (Dioscorea villosa)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT **Carbohydrates**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT **Fructooligosaccharides**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Aging, animal
(elderly; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glyco-; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Nettle
(leaf powder; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Ginkgo biloba
(leaf power; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Embryophyta
(medicinal plant, exts.; dietary supplement for stimulating release of

- human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Drug delivery systems
(oral; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Chlorella
(powder; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Drug delivery systems
(powders; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Intestinal bacteria
(probiotic, blends; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Yam (Dioscorea)
(root powder; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Pituitary gland
(secretagogues; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Diet
(supplements; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT Lepidium meyenii
(tuber powder; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT 56-12-2D, .gamma.-Aminobutyric acid, glyco derivs. 56-40-6D, Glycine, glyco derivs. 56-85-9D, L-Glutamine, glyco derivs. 70-18-8, L-Glutathione, biological studies 107-43-7, Trimethylglycine 303-98-0, Coenzyme Q10 501-36-0, Resveratrol 518-82-1, Emodin 520-27-4, Diosmin 566-19-8 616-91-1, N-Acetylcysteine 657-27-2D, L-Lysine monohydrochloride, glyco derivs. 1200-22-2, .alpha.-Lipoic acid 3040-38-8, Acetyl-L-carnitine 6151-25-3, Quercetin dihydrate 28319-77-9, L-.alpha.-Glycerolphosphorylcholine 29908-03-0, S-Adenosyl-L-methionine 56265-06-6D, glyco derivs. 408496-12-8, Symbiotropin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT 59-92-7, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plant-derived source of; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT 9004-10-8, Insulin, biological studies 67763-96-6, Insulin-like growth factor 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulators; dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)
- IT 9004-10-8, Insulin, biological studies 67763-96-6, Insulin-like growth factor 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulators; dietary supplement for stimulating release of human growth

hormone and promoting **healthy** hormonal balance in humans)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE


- (1) Cochran; US 6048846 A 2000 HCAPLUS
- (2) Jamieson, J; The Role of Somatotroph-Specific Peptides and IGF-1 Intermediates as an Alternative to High Injections, 1997
- (3) Lardy; US 5292730 A 1994 HCAPLUS
- (4) Lardy; US 5585371 A 1996 HCAPLUS
- (5) Lardy; US 5641766 A 1997 HCAPLUS
- (6) Partridge; US 5296481 A 1994 HCAPLUS

IT 107-43-7, Trimethylglycine 1200-22-2, .alpha.-Lipoic acid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement for stimulating release of human growth hormone and promoting **healthy** hormonal balance in humans)

RN 107-43-7 HCAPLUS


CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1200-22-2 HCAPLUS

CN 1,2-Dithiolane-3-pentanoic acid, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L114 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:10980 HCAPLUS

DN 136:74665

TI **Nutritional** system for nervous system disorders

IN Foreman, David J.

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K045-00

ICS A61K031-715; A61K035-80; A61K035-78

NCL 424093300

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002001575	A1	20020103	US 2001-865040	20010524
PRAI	US 2000-207665P	P	20000526		

AB A novel compn. for treating nervous system disorders. The compn. is formed by prepg. a mixt. comprising an effective amt. of **vitamin B-6, folic acid, vitamin C, magnesium, vitamin B-3, copper, probiotics, fructo-oligosaccharide (FOS), betaine, pancreatin, papain, pepsin, vitamin B-1, vitamin B-2, vitamin B-12, biotin, pantothenic acid, chromium polynicotinate** and a digestive support ingredient selected from the group consisting of dandelion root, juniper, aloe vera, burdock,

ginger root, artichoke, and kelp. Other ingredients may include: beta carotene, **vitamin E**, selenium, **zinc**, sea vegetation, alfalfa, trace **minerals** and molybdenum.

- ST **nutrient** soln nervous system disorder
- IT Ginseng (Panax)
(Siberian; **nutritional** system for nervous system disorders)
- IT Barberry (Berberis)
Elm (Ulmus)
(bark; **nutritional** system for nervous system disorders)
- IT Caulophyllum thalictroides
(blue cohosh; **nutritional** system for nervous system disorders)
- IT Eupatorium perfoliatum
(boneset; **nutritional** system for nervous system disorders)
- IT Nervous system
(disease; **nutritional** system for nervous system disorders)
- IT Rose (Rosa)
(hips; **nutritional** system for nervous system disorders)
- IT **Alfalfa (Medicago sativa)**
Aloe barbadensis
Artichoke (Cynara scolymus)
Burdock
Capsicum
Centella asiatica
Chamomile
Chrysanthemum parthenium
Clover (Trifolium pratense)
Ginkgo biloba
Hop (Humulus)
Juniper (Juniperus)
Nutrients
Parsley (Petroselinum crispum)
Peppermint (Mentha piperita)
Pollen
Rubus idaeus
Ruscus aculeatus
Seaweed
Spirulina
(**nutritional** system for nervous system disorders)
- IT **Fructooligosaccharides**
Vitamins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**nutritional** system for nervous system disorders)
- IT Intestinal bacteria
(probiotic; **nutritional** system for nervous system disorders)
- IT Asparagus
Dandelion
Ginger
Hydrangea
(root; **nutritional** system for nervous system disorders)
- IT Drug delivery systems
(solns.; **nutritional** system for nervous system disorders)
- IT Rumex crispus
(yellow dock; **nutritional** system for nervous system disorders)
- IT 50-81-7, **Vitamin c**, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, **Vitamin b1**, biological studies 59-67-6D, Nicotinic acid, polymers 68-19-9, **Vitamin b12** 79-83-4, **Vitamin b3** 83-88-5, **Vitamin b2**, biological studies 98-92-0, **Vitamin b3** 107-43-7, **Betaine** 590-46-5, **Betaine hydrochloride**

1406-18-4, Vitamin e 7235-40-7,
 .beta.-Carotene 7439-95-4, Magnesium, biological
 studies 7439-98-7, Molybdenum, biological studies 7440-47-3, Chromium,
 biological studies 7440-50-8, Copper, biological
 studies 7440-66-6, Zinc, biological studies
 7782-49-2, Selenium, biological studies 8049-47-6, Pancreatin
 8059-24-3, Vitamin b6 9001-73-4, Papain 9001-75-6,
 Pepsin

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)

(nutritional system for nervous system disorders)

IT 50-81-7, Vitamin c, biological studies 59-30-3
 , Folic acid, biological studies 59-43-8, Vitamin b1,
 biological studies 59-67-6D, Nicotinic acid, polymers
 68-19-9, Vitamin b12 79-83-4, Vitamin
 b3 83-88-5, Vitamin b2, biological studies
 107-43-7, Betaine 1406-18-4, Vitamin
 e 7439-95-4, Magnesium, biological studies
 7440-50-8, Copper, biological studies 7440-66-6
 , Zinc, biological studies 8059-24-3, Vitamin
 b6


RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)

(nutritional system for nervous system disorders)

RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3 HCAPLUS



CN L-Glutamic acid, N-[4-[[[2-amino-1,4-dihydro-4-oxo-6-
 pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-
 4-methyl- chloride (9CI) (CA INDEX NAME)




RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 68-19-9 HCAPLUS
CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 79-83-4 HCAPLUS

CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 83-88-5 HCAPLUS

CN Riboflavin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107-43-7 HCAPLUS

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CO}_2^-$

RN 1406-18-4 HCAPLUS
CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-95-4 HCAPLUS
CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-50-8 HCAPLUS
CN Copper (7CI, 8CI, 9CI) (CA INDEX NAME)

Cu

RN 7440-66-6 HCAPLUS
CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 8059-24-3 HCAPLUS
CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:833099 HCAPLUS

DN 135:362605

TI **Nutritional** preparation comprising **ribose** and folic acid and medical use thereof

IN **Hageman, Robert Johan Joseph; Smeets, Rudolf Leonardus Lodewijk; Verlaan, George**

PA N.V. **Nutricia**, Neth.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-7004

ICS A61K031-522; A23L001-09; A23L001-302; A61P003-00; A61P003-02; A61P039-06

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2001085178	A1	20011115	WO 2001-NL349	20010508
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,			

UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6420342 B1 20020716 US 2000-566381 20000508

EP 1282426 A1 20030212 EP 2001-930315 20010508

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2002183263 A1 20021205 US 2002-178736 20020625

PRAI US 2000-566381 A 20000508

WO 2001-NL349 W 20010508

AB Trauma, surgery, inflammation, subfertility, lactation problems, gut disorders, infant **nutrition**, cancer, arthritis and other joint problems, vascular problems and cardio- or cerebrovascular problems, ischemia, aging, impaired immune function, burns, sepsis, malnutrition, problems with liver or kidneys, malaria, cystic fibrosis, migraine, neurol. problems, respiratory infections, improvement of sports results, muscle soreness, drug intoxication and pain can be treated with a **nutritional** compn. contg. effective amts. of **ribose** and folic acid, optionally combined with other components such as niacin, histidine, glutamine, orotate, **vitamin B6** and other components.

ST **nutrition** pharmaceutical **ribose** folic acid

IT Nervous system

(Huntington's chorea; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Digestive tract

Nervous system

(disease; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Fertility

Lactation

(disorder; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Poisoning, biological

(drug; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Respiratory tract

(infection; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Nucleotides, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(metab.; **nutritional** prepn. comprising **ribose** and folic acid and medical use)

IT Alzheimer's disease

Analgesics

Antiarthritics

Antidepressants

Antitumor agents

Burn

Cardiovascular agents

Cystic fibrosis

Fatigue, biological

Immunity

Kidney, disease

Liver, disease

Malnutrition

Multiple sclerosis

Parkinson's disease

Schizophrenia

Sepsis

Surgery

Tuberculostatics

(**nutritional** prepn. comprising **ribose** and folic

acid and medical use)

IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nutritional prepn. comprising ribose and folic acid and medical use)

IT Amino acids, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional prepn. comprising ribose and folic acid and medical use)

IT Muscle
 (soreness; nutritional prepn. comprising ribose and folic acid and medical use)

IT Diet
 (supplements; nutritional prepn. comprising ribose and folic acid and medical use)

IT Injury
 (trauma; nutritional prepn. comprising ribose and folic acid and medical use)

IT 69-93-2, Uric acid, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidant; nutritional prepn. comprising ribose and folic acid and medical use)

IT 50-99-7, D-Glucose, biological studies 56-85-9, Glutamine, biological studies 56-87-1, L-Lysine, biological studies 57-00-1, Creatine 59-43-8, Thiamine, biological studies 59-67-6, Niacin, biological studies 61-90-5, L-Leucine, biological studies 63-68-3, L-Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 65-86-1, Orotic acid 68-19-9, Vitamin b12 71-00-1, L-Histidine, biological studies 72-19-5, L-Threonine, biological studies 73-32-5, L-Isoleucine, biological studies 77-92-9, Citric acid, biological studies 107-35-7, Taurine 107-43-7, Betaine 303-98-0, Coenzyme q10 541-15-1, Carnitine 1200-22-2, .alpha.-Lipoic acid 7439-95-4, Magnesium, biological studies 7440-66-6, Zinc, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin b6 14265-44-2, Phosphate, biological studies 14808-79-8, Sulfate, biological studies
 RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional prepn. comprising ribose and folic acid and medical use)

IT 50-69-1, D-Ribose 59-30-3, Folic acid, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional prepn. comprising ribose and folic acid and medical use)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bioenergy Inc; WO 9965476 A 1999 HCAPLUS
 (2) Depha Team SRL; WO 9215311 A 1992 HCAPLUS
 (3) Naito, A; EP 0652012 A 1995 HCAPLUS
 (4) Oster, K; DE 2231989 A 1973 HCAPLUS
 (5) Oy Jurilab Ltd; WO 0128365 A 2001 HCAPLUS


IT 50-99-7, D-Glucose, biological studies 63-68-3, L-Methionine, biological studies 77-92-9, Citric acid, biological studies 107-35-7, Taurine 107-43-7, Betaine 1200-22-2, .alpha.-Lipoic acid 7439-95-4, Magnesium, biological studies 7440-66-6, Zinc, biological studies
 RL: FFD (Food or feed use); MOA (Modifier or additive use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(**nutritional** prepn. comprising **ribose** and folic
acid and medical use)

RN 50-99-7 HCAPLUS

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 63-68-3 HCAPLUS


CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77-92-9 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 107-35-7 HCAPLUS

CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)



RN 107-43-7 HCAPLUS


CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1200-22-2 HCAPLUS

CN 1,2-Dithiolane-3-pentanoic acid, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 7439-95-4 HCAPLUS
 CN Magnesium (8CI, 9CI) (CA INDEX NAME)


Mg

RN 7440-66-6 HCAPLUS
 CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

IT **50-69-1, D-Ribose**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional prepn. comprising **ribose** and folic acid and medical use)
 RN 50-69-1 HCAPLUS
 CN D-Ribose (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L114 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2003 ACS
 AN **1999:77453** HCAPLUS
 DN **130:152854**
 TI **Nutritional** composition containing **methionine**.
 IN **Hageman, Robert Johan Joseph**
 PA N.V. **Nutricia**, Neth.
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A23L001-305
 ICS A61K031-195; A23L001-302; A23L001-304; A61K033-30
 CC 17-6 (**Food** and **Feed** Chemistry)
 Section cross-reference(s): 63
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9903365	A1	19990128	WO 1998-NL408	19980714
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9884658	A1	19990210	AU 1998-84658	19980714
	EP 1001685	A1	20000524	EP 1998-935394	19980714
	R: AT, BE, CH, DE, DK, FR, GB, LI, NL, SE, FI				

JP 2001510145 T2 20010731 JP 2000-502681 19980714
 US 2002142025 A1 20021003 US 2000-462757 20000131
 PRAI EP 1997-202206 A 19970714
 WO 1998-NL408 W 19980714

AB An enteral **nutrient** compn. for clin. or dietary use, comprises, in addn. to **carbohydrates** and proteins or their hydrolyzates the following components or their **nutritional** equiv., per daily dosage: **methionine** (0.6-7 g), cysteine (0.5-2.5 g), folic acid (0.4-8 mg), pyridoxal (**vitamin B6**) (3-20 mg), **zinc** (18-120 mg) and at least 400 kcal energy in the form of **carbohydrates**. These amts. are well above the Recommended Daily Allowance (RDA) values. Further preferred components include lecithin, cyanocobalamine, **betaine** and **magnesium**, as well as transsulfuration metabolites, ATP enhancers and antioxidants.

ST diet therapeutic **methionine nutrient**; enteral diet therapeutic **methionine nutrient**

IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (algae; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Skin, disease
 Skin, disease
 (decubitus ulcer; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Cardiovascular system
 (disease; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Immunity
 (disorder; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT **Nutrients**
 (enteral; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fish; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Syrups (sweetening agents)
 (**glucose**; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Wheat
 (hydrolyzate; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Glycerides, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medium-chain; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Proteins, general, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (milk; **nutritional** compn. contg. **methionine** for clin. and dietary enteral application)

IT Aging, animal
 Allergy
 Antitumor agents
 Arthritis
 Autoimmune disease
 Dietary energy
 Dietary fiber
 Inflammation

Neoplasm
 Nerve, disease
 Wound healing
 (nutritional compn. contg. **methionine** for clin. and dietary enteral application)

IT Amino acids, biological studies
 Canola oil
Carbohydrates, biological studies
Mineral elements, biological studies
 Nucleotides, biological studies
 Phospholipids, biological studies
 Protein hydrolyzates
 Proteins, general, biological studies
 Rape oil
 Sunflower oil
Trace element nutrients
Vitamins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nutritional compn. contg. **methionine** for clin. and dietary enteral application)

IT Lecithins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (soya; **nutritional compn. contg. methionine** for clin. and dietary enteral application)

IT **Diet**
 (therapeutic; **nutritional compn. contg. methionine** for clin. and dietary enteral application)

IT Proteins, specific or class
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (whey; **nutritional compn. contg. methionine** for clin. and dietary enteral application)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, L-Cysteine, biological studies 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 57-00-1, Creatine 57-50-1, Sucrose, biological studies 58-85-5, Biotin 59-02-9, .alpha.-**Tocopherol** 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 63-68-3, L-**Methionine**, biological studies 66-72-8, Pyridoxal 67-48-1, Choline chloride 68-19-9, **Vitamin B12** 70-26-8, L-Ornithine 73-22-3, L-Tryptophan, biological studies 74-79-3, L-Arginine, biological studies 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 98-92-0, Nicotinamide 107-35-7, **Taurine** 107-43-7, **Betaine** 127-17-3, Pyruvic acid, biological studies 134-03-2, **Sodium** ascorbate 541-15-1, Carnitine 866-84-2, **Potassium citrate** 1077-28-7, Thioctic acid 1406-18-4, **Vitamin E** 7439-89-6, **Iron**, biological studies 7439-95-4, **Magnesium**, biological studies 7439-96-5, Manganese, biological studies 7439-98-7, Molybdenum, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, **Copper**, biological studies 7440-66-6, **Zinc**, biological studies 7553-56-2, Iodine, biological studies 7647-14-5, **Sodium** chloride, biological studies 7733-02-0, **Zinc** sulfate 7758-98-7, **Copper** sulfate, biological studies 7782-41-4, Fluorine, biological studies 7782-49-2, Selenium, biological studies 7785-87-7, Manganese sulfate 9050-36-6, Maltodextrin 10043-83-1, **Magnesium phosphate** 10103-46-5, **Calcium phosphate** 13410-01-0, **Sodium** selenate

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nutritional compn. contg. **methionine** for clin. and dietary enteral application)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, L-Cysteine, biological studies 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 57-00-1, Creatine 57-50-1, Sucrose, biological studies 58-85-5, Biotin 59-02-9, .alpha.-**Tocopherol** 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 63-68-3, L-**Methionine**, biological studies 66-72-8, Pyridoxal 67-48-1, Choline chloride 68-19-9, **Vitamin B12** 70-26-8, L-Ornithine 73-22-3, L-Tryptophan, biological studies 74-79-3, L-Arginine, biological studies 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 98-92-0, Nicotinamide 107-35-7, **Taurine** 107-43-7, **Betaine** 127-17-3, Pyruvic acid, biological studies 134-03-2, **Sodium** ascorbate 541-15-1, Carnitine 866-84-2, **Potassium citrate** 1077-28-7, Thioctic acid 1406-18-4, **Vitamin E** 7439-89-6, **Iron**, biological studies 7439-95-4, **Magnesium**, biological studies 7439-96-5, Manganese, biological studies 7439-98-7, Molybdenum, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, **Copper**, biological studies 7440-66-6, **Zinc**, biological studies 7553-56-2, Iodine, biological studies 7647-14-5, **Sodium** chloride, biological studies 7733-02-0, **Zinc** sulfate 7758-98-7, **Copper** sulfate, biological studies 7782-41-4, Fluorine, biological studies 7782-49-2, Selenium, biological studies 7785-87-7, Manganese sulfate 9050-36-6, Maltodextrin 10043-83-1, **Magnesium phosphate** 10103-46-5, **Calcium phosphate** 13410-01-0, **Sodium** selenate

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nutritional compn. contg. **methionine** for clin. and dietary enteral application)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bissbort, S; EP 0532369 A 1993 HCAPLUS
- (2) Gitta Carmen Conway; GB 2292522 A 1996 HCAPLUS
- (3) Keane, M; US 5215750 A 1993 HCAPLUS
- (4) Luca, M; EP 0482715 A 1992
- (5) Millman, P; EP 0259167 A 1988 HCAPLUS

IT 50-81-7, Ascorbic acid, biological studies 59-02-9, .alpha.-**Tocopherol** 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 63-68-3, L-**Methionine**, biological studies 68-19-9, **Vitamin B12** 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 107-35-7, **Taurine** 107-43-7, **Betaine** 134-03-2, **Sodium** ascorbate 1406-18-4, **Vitamin E** 7439-89-6, **Iron**, biological studies 7439-95-4, **Magnesium**, biological studies 7440-50-8, **Copper**, biological studies 7440-66-6, **Zinc**, biological studies


RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nutritional compn. contg. **methionine** for clin. and dietary enteral application)

RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-02-9 HCAPLUS

CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3 HCAPLUS


CN L-Glutamic acid, N-[4-[(2-amino-1,4-dihydro-4-oxo-6-pteridiny)methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)




RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 63-68-3 HCAPLUS
CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68-19-9 HCAPLUS
CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 79-83-4 HCAPLUS
 CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 83-88-5 HCAPLUS
CN Riboflavin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 107-35-7 HCAPLUS
CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)




RN 107-43-7 HCAPLUS
CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 134-03-2 HCAPLUS
CN L-Ascorbic acid, monosodium salt (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 1406-18-4 HCAPLUS
CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

RN 7439-95-4 HCAPLUS
CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-50-8 HCAPLUS
CN Copper (7CI, 8CI, 9CI) (CA INDEX NAME)

Cu

RN 7440-66-6 HCAPLUS
CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

L114 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:64536 HCAPLUS
DN 130:124200
TI Nutritional composition containing methionine
IN Hageman, Robert Johan Joseph
PA N.V. Nutricia, Neth.
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A23L001-305
ICS A61K031-195; A23L001-302; A23L001-304; A61K033-30
CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): 18, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 891719	A1	19990120	EP 1997-202206	19970714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AU 9884658	A1	19990210	AU 1998-84658	19980714
	EP 1001685	A1	20000524	EP 1998-935394	19980714
	R: AT, BE, CH, DE, DK, FR, GB, LI, NL, SE, FI				
	JP 2001510145	T2	20010731	JP 2000-502681	19980714
	US 2002142025	A1	20021003	US 2000-462757	20000131
PRAI	EP 1997-202206	A	19970714		
	WO 1998-NL408	W	19980714		
AB	An enteral food compn. for clin. or dietary use comprises, in addn. to carbohydrates and proteins or their hydrolyzates the following components or their nutritional equiv., per daily dosage: methionine (0.6-7 g), cysteine (0.5-2.5 g), folic acid (0.4-8 mg), pyridoxal (vitamin B6) (3-20 mg), zinc (18-120 mg) and at least 400 kcal energy in the form of carbohydrates . These amts. are well above the Recommended Daily Allowance (RDA) values. Further preferred components include lecithin, cyanocobalamine, betaine and magnesium , as well as transsulfuration metabolites, ATP enhancers and antioxidants.				
ST	food methionine vitamin mineral				
	supplement				
IT	Cardiovascular system				
	(disease; nutritional compn. contg. methionine)				
IT	Caseins, biological studies				
	RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(metal complexes; nutritional compn. contg. methionine)				
IT	Allergy				
	Antioxidants				
	Arthritis				
	Autoimmune disease				
	Dietary energy				
	Immunity				
	Inflammation				
	Neoplasm				
	Nerve, disease				
	Surgery				
	Wound healing				
	(nutritional compn. contg. methionine)				
IT	Amino acids, biological studies				
	Carbohydrates, biological studies				
	Lecithins				
	Lipids, biological studies				
	Mineral elements, biological studies				
	Nucleotides, biological studies				
	Protein hydrolyzates				
	Proteins, general, biological studies				
	Tocopherols				
	Vitamins				
	RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(nutritional compn. contg. methionine)				
IT	Aging, animal				
	(premature; nutritional compn. contg. methionine)				
IT	Diet				
	(therapeutic; nutritional compn. contg. methionine)				
IT	74-79-3, L-Arginine, biological studies				
	RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

(7nutritional compn. contg. **methionine**)

IT 56-65-5, ATP, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enhancers of; **nutritional compn. contg. methionine**)


IT 50-81-7, **Vitamin C**, biological studies 52-90-4, L-Cysteine, biological studies 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 57-00-1, Creatine 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 63-68-3, L-Methionine, biological studies 66-72-8, Pyridoxal 68-19-9, Cyanocobalamin 70-26-8, L-Ornithine 83-88-5, Riboflavin, biological studies 107-35-7, **Taurine** 107-43-7, **Betaine** 127-17-3, Pyruvic acid, biological studies 541-15-1, Carnitine 616-91-1, N-Acetylcysteine 1077-28-7, Thiocetic acid 1406-18-4, **Vitamin E** 6027-13-0, Homocysteine 7439-95-4, **Magnesium**, biological studies 7439-96-5, Manganese, biological studies 7440-50-8, **Copper**, biological studies 7440-66-6, **Zinc**, biological studies 7782-49-2, Selenium, biological studies 9050-36-6, Maltodextrin
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**nutritional compn. contg. methionine**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Bissbort, S; EP 0532369 A HCAPLUS
 (2) Gitta, C; GB 2292522 A HCAPLUS
 (3) Keane, M; US 5215750 A HCAPLUS
 (4) Luca, M; EP 0482715 A
 (5) Millman, P; EP 0259167 A HCAPLUS

IT 50-81-7, **Vitamin C**, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 63-68-3, L-Methionine, biological studies 68-19-9, Cyanocobalamin 83-88-5, Riboflavin, biological studies 107-35-7, **Taurine** 107-43-7, **Betaine** 1406-18-4, **Vitamin E** 7439-95-4, **Magnesium**, biological studies 7440-50-8, **Copper**, biological studies 7440-66-6, **Zinc**, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**nutritional compn. contg. methionine**)


RN 50-81-7 HCAPLUS
 CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-30-3 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59-43-8 HCAPLUS


CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 59-67-6 HCAPLUS


CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)



RN 63-68-3 HCAPLUS

CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68-19-9 HCAPLUS

CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 83-88-5 HCAPLUS
 CN Riboflavin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


Y



RN 107-35-7 HCAPLUS
 CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)



RN 107-43-7 HCAPLUS
 CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1406-18-4 HCAPLUS
 CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-95-4 HCAPLUS
 CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-50-8 HCAPLUS
 CN Copper (7CI, 8CI, 9CI) (CA INDEX NAME)

Cu

RN 7440-66-6 HCAPLUS
 CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

L114 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:744961 HCAPLUS

DN 130:7433

TI Treatment of sickle cell disease, treatment of immune system

diseases and other diseases normally associated with **sickle cell anemia**

IN Lockett, Curtis

PA USA

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K033-32

ICS A61K033-24; A61K033-36; A61K033-04; A61K033-06; A61K035-78;
A61K031-70; A61K031-51; A61K031-44; A61K031-355; A61K031-34;
A61K031-07

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850051	A1	19981112	WO 1997-US7122	19970505
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9729932	A1	19981127	AU 1997-29932	19970505
PRAI	WO 1997-US7122	A	19970505		
AB	A maintenance regimen with controlled intake of particular vitamin , mineral , and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A , vitamin B-1 , vitamin B-2 , vitamin B-6 , vitamin B-12 , vitamin C , vitamin D , vitamin E , niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol , rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium , iron , magnesium , zinc , potassium , manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below crit. satn. levels, detd. for each individual by carefully monitoring tolerance on titrn. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the prodn. of viable Hb, and alters the overall blood profile. Platelet concn. is increased up to twice that seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manuf. without substantial feedback control by the upper central nervous system.				
ST	sickle cell disease treatment vitamin mineral micronutrient formulation; immune system disease treatment vitamin mineral micronutrient formulation				
IT	Flavonoids RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bioflavonoids, citrus, complex; treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with vitamin and mineral and micronutrient formulations in humans)				
IT	Immunity (disorder; treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell				

- anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT Organ, animal
Organ, animal
(failure; treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT **Nutrients**
(micronutrients; treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT Drug delivery systems
(sustained-release; treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT Sickle cell anemia
(treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT **Mineral elements, biological studies**
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)
- IT 50-81-7, **Vitamin C**, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, **Vitamin B-1**, biological studies 68-19-9, **Vitamin B-12** 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-67-2, Choline bitartrate, biological studies 87-89-8, **Inositol** 98-92-0, Niacinamide 150-13-0, p-Aminobenzoic acid 153-18-4, Rutin 590-46-5, **Betaine** hydrochloride 1406-16-2, **Vitamin D** 1406-18-4, **Vitamin E** 7439-89-6, Iron, biological studies 7439-95-4, **Magnesium**, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, **Potassium**, biological studies 7440-47-3, Chromium, biological studies 7440-66-6, **Zinc**, biological studies 7440-70-2, **Calcium**, biological studies 7553-56-2, Iodine, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, **Vitamin B-6** 11103-57-4, **Vitamin A** 12002-36-7, Hesperidin complex
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Chima; US 4904678 A 1990 HCAPLUS
- (2) Hider; US 4866052 A 1989 HCAPLUS
- (3) Ohnishi; US 5114972 A 1992 HCAPLUS
- (4) Walaszek; US 5364644 A 1994 HCAPLUS
- (5) Wilburn; US 5108754 A 1992 HCAPLUS

IT 50-81-7, Vitamin C, biological studies 59-30-3
 , Folic acid, biological studies 59-43-8, Vitamin B-1,
 biological studies 68-19-9, Vitamin B-12
 79-83-4, Pantothenic acid 83-88-5, Riboflavin,
 biological studies 87-89-8, Inositol 1406-16-2
 , Vitamin D 1406-18-4, Vitamin E
 7439-89-6, Iron, biological studies 7439-95-4,
 Magnesium, biological studies 7440-09-7,
 Potassium, biological studies 7440-66-6, Zinc,
 biological studies 7440-70-2, Calcium, biological
 studies 8059-24-3, Vitamin B-6 11103-57-4,
 Vitamin A


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with **vitamin** and **mineral** and micronutrient formulations in humans)

RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3 HCAPLUS


CN L-Glutamic acid, N-[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)




RN 68-19-9 HCAPLUS
 CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 79-83-4 HCAPLUS

CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 83-88-5 HCAPLUS

CN Riboflavin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 87-89-8 HCAPLUS

CN myo-Inositol (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 1406-16-2 HCAPLUS

CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1406-18-4 HCAPLUS

CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-89-6 HCAPLUS

CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-09-7 HCAPLUS

CN Potassium (8CI, 9CI) (CA INDEX NAME)

K

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 8059-24-3 HCAPLUS

CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11103-57-4 HCAPLUS

CN Vitamin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:321923 HCAPLUS

DN 126:347291

TI **Vitamins and minerals** for the treatment of
sickle cell disease

IN Lockett, Curtis G.

PA Lockett, Curtis G., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K033-32

ICS A61K033-24; A61K033-36; A61K033-06; A61K033-04; A61K035-78;
A61K031-70; A61K031-51; A61K031-44; A61K031-355; A61K031-34;
A61K031-07

NCL 424639000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5626884	A	19970506	US 1995-516737	19950818
PRAI	US 1995-516737		19950818		

AB A maintenance regimen with controlled intake of particular **vitamin**, **mineral**, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include **vitamin A**, **vitamin B1**, **vitamin B2**, **vitamin B6**, **vitamin B12**, **vitamin C**, **vitamin D**, **vitamin E**, niacinamide, p-aminobenzoic acid, pantothenic acid, choline bitartrate, **inositol**, rutin, citrus bioflavonoid complex, **betaine**.cntdot.HCl, hesperidin complex, folic acid, biotin, **calcium**, **iron**, **magnesium**, **zinc**, **potassium**, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below crit. satn. levels, detd. for each individual by carefully monitoring tolerance on titrn. The daily dose may exceed that necessary as dietary or **nutritional** supplements, and trigger an increase in the prodn. of viable Hb, and alters the overall blood profile. Platelet concn. is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manuf. without substantial **feedback** control by the upper central nervous system.

ST **vitamin mineral** sickle cell disease

IT Flavonoids

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bioflavonoids; **vitamins** and **minerals** for treatment of sickle cell disease)

IT Drug delivery systems

(sustained-release; **vitamins** and **minerals** for treatment of sickle cell disease)

IT Sickle cell anemia

(**vitamins** and **minerals** for treatment of sickle cell disease)

IT **Minerals**, biological studies

Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamins and minerals for treatment of sickle cell disease)

IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin; 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B-1, biological studies 68-19-9, Vitamin B-12 79-83-4, Pantothenic acid 83-88-5, Vitamin B-2, biological studies 87-67-2, Choline bitartrate, biological studies 87-89-8, Inositol 98-92-0, Niacinamide 150-13-0 153-18-4, Rutin 520-26-3D, Hesperidin, complexes 590-46-5, Betaine hydrochloride 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7439-89-6, Iron;, biological studies 7439-95-4, Magnesium;, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium;, biological studies 7440-47-3, Chromium;, biological studies 7440-66-6, Zinc;, biological studies 7440-70-2, Calcium;, biological studies 7553-56-2, Iodine;, biological studies 7782-49-2, Selenium., biological studies 8059-24-3, Vitamin B-6 11103-57-4, Vitamin A

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamins and minerals for treatment of sickle cell disease)

IT 50-81-7, Vitamin C, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B-1, biological studies 68-19-9, Vitamin B-12 79-83-4, Pantothenic acid 83-88-5, Vitamin B-2, biological studies 87-89-8, Inositol 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7439-89-6, Iron;, biological studies 7439-95-4, Magnesium;, biological studies 7440-09-7, Potassium;, biological studies 7440-66-6, Zinc;, biological studies 7440-70-2, Calcium;, biological studies 8059-24-3, Vitamin B-6 11103-57-4, Vitamin A


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamins and minerals for treatment of sickle cell disease)

RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3 HCAPLUS


CN L-Glutamic acid, N-[4-[[[2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)




● Cl⁻


RN 68-19-9 HCAPLUS

CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 79-83-4 HCAPLUS

CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 83-88-5 HCAPLUS


CN Riboflavin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 87-89-8 HCAPLUS
CN myo-Inositol (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 1406-16-2 HCAPLUS
CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1406-18-4 HCAPLUS
CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

RN 7439-95-4 HCAPLUS
CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-09-7 HCAPLUS
CN Potassium (8CI, 9CI) (CA INDEX NAME)

K

RN 7440-66-6 HCAPLUS
CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 8059-24-3 HCAPLUS
CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11103-57-4 HCAPLUS
CN Vitamin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:97785 HCAPLUS

DN 126:148521

TI Vitamin/mineral composition

IN Williams, Andrew H.; Williams, Eric A.

PA Williams, Andrew H., USA; Williams, Eric A.

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K035-28

ICS A61K035-26; A61K033-32; A61K033-24; A61K031-70; A61K031-34;
A61K031-355; A61K031-07

NCL 424579000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 18

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5597585	A	19970128	US 1995-578284	19951226
PRAI	US 1995-578284		19951226		

AB Vitamin/mineral nutritional mixt. in the
form of a dry powder sol. in water was described.

ST vitamin mineral compn

IT Spleen

Thymus gland

(conc.; vitamin/mineral compn.)

IT Mineral elements, biological studies

Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin/mineral compn.)

IT 50-81-7, Vitamin c, biological studies 52-90-4,
L-Cysteine, biological studies 58-85-5, Biotin 59-30-3, Folic
acid, biological studies 59-43-8, Vitamin b1,
biological studies 59-51-8, Methionine 59-67-6
, Niacin, biological studies 60-00-4, Edta, biological studies
62-49-7, Choline 68-19-9, Vitamin b12 79-83-4
, Pantothenic acid 83-88-5, Vitamin b2, biological
studies 87-89-8, Inositol 98-92-0, Niacinamide
107-43-7, Betaine 1406-18-4, Vitamin
e 7439-95-4, Magnesium, biological studies
7439-96-5, Manganese, biological studies 7440-09-7,
Potassium, biological studies 7440-47-3, Chromium, biological
studies 7440-66-6, Zinc, biological studies
7782-49-2, Selenium, biological studies 8059-24-3,
Vitamin b6 11103-57-4, Vitamin a
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin/mineral compn.)

IT 50-81-7, Vitamin c, biological studies 59-30-3
, Folic acid, biological studies 59-43-8, Vitamin b1,
biological studies 59-51-8, Methionine 59-67-6
, Niacin, biological studies 68-19-9, Vitamin b12
79-83-4, Pantothenic acid 83-88-5, Vitamin b2,
biological studies 87-89-8, Inositol 107-43-7
, Betaine 1406-18-4, Vitamin e
7439-95-4, Magnesium, biological studies
7440-09-7, Potassium, biological studies

7440-66-6, Zinc, biological studies 8059-24-3,

Vitamin b6 11103-57-4, Vitamin a


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamin/mineral compn.)

RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-30-3 HCAPLUS


CN L-Glutamic acid, N-[4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-43-8 HCAPLUS

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- chloride (9CI) (CA INDEX NAME)


● Cl⁻

RN 59-51-8 HCAPLUS

CN Methionine (9CI) (CA INDEX NAME)




RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 68-19-9 HCAPLUS
CN Vitamin B12 (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 79-83-4 HCAPLUS

CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 83-88-5 HCAPLUS

CN Riboflavin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 87-89-8 HCAPLUS


CN myo-Inositol (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 107-43-7 HCAPLUS

CN Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 1406-18-4 HCAPLUS

CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-09-7 HCAPLUS

CN Potassium (8CI, 9CI) (CA INDEX NAME)

K

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 8059-24-3 HCAPLUS

CN Vitamin B6 (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11103-57-4 HCAPLUS

CN Vitamin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L114 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2003 ACS

AN 1990:62458 HCAPLUS

DN 112:62458

TI Absorption of water and solute from glucose-electrolyte solutions in the human jejunum: effect of **citrate** or betaine

AU Leiper, John B.; Maughan, R. J.

CS Dep. Environ. Occup. Med., Univ. Med. Sch., Foresterhill/Aberdeen, AB9
22D, UK

SO Scandinavian Journal of Gastroenterology (1989), 24(9), 1089-94
CODEN: SJGRA4; ISSN: 0036-5521

DT Journal

LA English

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1

AB Using a modified perfusion system, water and solute absorption in the
normal human intestine from two effervescent glucose-electrolyte solns.,
contg. either **citrate** or betaine-HCl, was examd. and the
absorption rates were compared with those from a commonly used
bicarbonate-contg. oral rehydration soln. Absorption of **citrate**
(355 .mu.mol/cm/h) and betaine (313 .mu.mol/cm/h) occurred from the resp.
solns. The inclusion of 46 mmol/L **citrate** or 36 mmol/L betaine
in effervescent oral rehydration solns. had no effect on water or solute
absorption.

ST oral rehydration soln glucose electrolyte; intestine absorption water
solute rehydration soln; **citrate** betaine intestine absorption
rehydration

IT Electrolytes
(rehydration oral solns. contg., water and solute absorption by human
intestine from, betaine and **citrate** effect on)

IT Intestine, metabolism
(jejunum, water and solute absorption by human, from
glucose-electrolyte rehydration solns., betaine and **citrate**
effect on)

IT Hydration, biological
(re-, glucose-electrolyte solns. for, water and solute absorption by
human intestine from, betaine and **citrate** effect on)

IT Pharmaceutical dosage forms
(tablets, effervescent, rehydration oral soln. from, water and solute
absorption by human intestine from, betaine and **citrate**
effect on)

IT 7732-18-5
RL: BIOL (Biological study)
(electrolytes, rehydration oral solns. contg., water and solute
absorption by human intestine from, betaine and **citrate**
effect on)

IT 77-92-9, biological studies 107-43-7
RL: BIOL (Biological study)
(rehydration oral soln. contg., water and solute absorption by human
intestine in relation to)

IT 77-92-9, biological studies 107-43-7
RL: BIOL (Biological study)
(rehydration oral soln. contg., water and solute absorption by human
intestine in relation to)

=> fil wpix
FILE 'WPIX' ENTERED AT 13:27:12 ON 10 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 7 MAR 2003 <20030307/UP>
MOST RECENT DERWENT UPDATE: 200316 <200316/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot 1125

L125 ANSWER 1 OF 3 WPIX (C) 2003 THOMSON DERWENT
AN 2002-608421 [65] WPIX
DNC C2002-172023
TI Fluid useful in the treatment of hypohydration comprises
methylamine, flavanolignan.
DC B05
IN HAGEMAN, R J J; SMEETS, R L L; VERLAAN, G
PA (HAGE-I) HAGEMAN R J J; (SMEE-I) SMEETS R L L; (VERL-I) VERLAAN G;
(NUTR-N) NUTRICIA NV
CYC 94
PI WO 2002058792 A2 20020801 (200265)* EN 22p A61P001-12 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AU AZ BA BB BG BR BY BZ CA CH CN CO CR DM DZ EC ES GB
GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SL TJ
TM TN TR TZ UA US UZ VN YU ZA ZM ZW
US 2002176881 A1 20021128 (200281) A61K047-00
ADT WO 2002058792 A2 WO 2002-NL63 20020128; US 2002176881 A1 US 2001-770773
20010126
PRAI US 2001-770773 20010126
IC ICM A61K047-00; A61P001-12
ICS A61K031-35; **A61K031-70**
AB WO 200258792 A UPAB: 20021010
NOVELTY - A fluid (I) comprises **methylamine** and/or
flavanolignan, at least one digestible carbohydrate, and at least one
mineral.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) A concentrate for preparation of (I); and
(2) a method for manufacturing the concentrate for preventing or
treating hypohydration.
ACTIVITY - Antidiarrheic.
MECHANISM OF ACTION - Insulin response modulator.
USE - In the treatment of hypohydration, gut disorder, cystic
fibrosis, cardiovascular disease and other symptomatically or
physiologically related disorder, dehydration of a subject (e.g. elderly
person) who is exposed to a high temperature and/or physical exercise; for
medical use (all claimed). In the prevention and/or treating the loss of
bodily water in humans and/or animals, water loss due to excessive
sweating, water loss due to diarrhea.
ADVANTAGE - (I) has hypotonic osmolarity of at most 300 mOsm/l and
dry mass content of at most 9 wt.%. (I) has a pH of 2.5 - 6.8 and nitrogen
content of less than 3 g/l. (I) improves the speed and efficiency of water
absorption by the body. (I) helps the body to maintain glucose- and
mineral homeostasis and contributes to the reduction of negative
side-effects associated with the disturbance in the homeostasis of water,
minerals, glucose and/or other endogenous compounds. (I) exhibits
modulating effect on the insulin response thus maintaining the glucose
balance in the blood plasma. (I) reduces the risk of diarrhea and risk of
developing muscle cramps.

Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: B04-C02; B04-D01; B05-A01A; B05-A01B; B05-A03A; B05-B02A; B05-C07;
 B06-A02; B07-A02; B07-B03; B10-A07; B10-A09B; B10-B02D; B10-C02;
 B10-E04C; **B12-M07**; B14-C03; B14-E10; B14-F01; B14-F02
 TECH UPTX: 20021010
 TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The carbohydrate comprises (g/l) glucose and at least one monosaccharide selected from fructose, galactose (0.5), mannose, ribose (0.5) or inositol (0.5).
 Preferred Composition: (I) comprises digestible carbohydrate in a concentration of 10 - 80 g/l and has an average chain length of 3 - 50 monosaccharide units. At least 50% of the carbohydrate is in the form of oligosaccharide or polysaccharide. The amount of fructose and mannose together is 0.05 - 0.6 mole/mole glucose. The **methylanine** is **betaine** and is present in a concentration of 0.1 - 20 g/l.
 Preferred Fluid: (I) further comprises (g/l) **glycerol** (0.1 - 20), **lipoic acid** (at least 20 mg/l), vitamin (preferably tocopherol), **citrate**, **phosphate**, **malate**, **taurine** (0.2 - 2) and/or **caffeine** (0.1 - 1) and **methionine**.
 TECHNOLOGY FOCUS - BIOLOGY - Preferred Components: The flavanolignan is **silibin** (0.1 - 8 g). The source of **silibin** is **silymarin** (0.2 - 10 g/l).
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Concentrate: The concentrate is in the form of pre-mix, powder, agglomerate, fluid, syrup, gel, tablet or capsule.
 TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The mineral (0.1 - 30 g/l) is selected from sodium, potassium, chloride, **phosphate**, magnesium (at least 100 mg/l), zinc (at least 10 mg/l), calcium (at least 300 mg/l), iron (at least 5 mg/l) or copper.
 ABEX ADMINISTRATION - (I) is administered orally in the form of water solution, fruit juice, whey dairy drink, beverage or as fluid by tube or enterally. (I) is administered before, during or after the subject is subjected to surgery (all claimed).
 EXAMPLE - A drink to support a person suffering from diarrhea was prepared by dissolving glucose (g) (6), ribose (1), inositol (0.2), fructose (2), maltodextrin (5), betaine (2), folic acid (microg), **methionine** (0.3), sodium (2.1), potassium (0.8), chloride (2.9) and **citrate** (1.9) in water (1 liter).
 L125 ANSWER 2 OF 3 WPIX (C) 2003 THOMSON DERWENT
 AN 2000-331250 [29] WPIX
 DNC C2000-100433
 TI Serumfree medical solution (I) comprises e.g. an aqueous nutrient and electrolyte solution, a glycosaminoglycan, a deturgescent agent and an energy source, maintains and enhances the preservation of mammalian tissues.
 DC A96 B01 B04 B05 D22
 IN SKELNIK, D L; SKELNIK, D A
 PA (SKEL-I) SKELNIK D L; (BAUL) BAUSCH & LOMB SURGICAL INC
 CYC 29
 PI EP 1000541 A1 20000517 (200029)* EN 27p A01N001-02
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 AU 9957108 A 20000511 (200031) A01N001-02
 CA 2288540 A1 20000505 (200039) EN A01N001-02

JP 2000198701 A 20000718 (200040) 19p A01N001-02
 US 6153582 A 20001128 (200063) A61K038-00
 ADT EP 1000541 A1 EP 1999-308702 19991102; AU 9957108 A AU 1999-57108
 19991028; CA 2288540 A1 CA 1999-2288540 19991103; JP 2000198701 A JP
 1999-313063 19991102; US 6153582 A US 1998-186580 19981105

PRAI US 1998-186580 19981105

IC ICM A01N001-02; A61K038-00

ICS A61K009-08; **A61K031-70**; C12N005-00

AB EP 1000541 A UPAB: 20000617

NOVELTY - Serum free medical solution (I) comprises e.g. an aqueous nutrient and electrolyte solution, a glycosaminoglycan, a deturgescent agent, a buffer system, an antioxidant, membrane stabilizing agents, an antibiotic or antimycotic agent, ATP or energy precursors, nutrient cell supplements, coenzymes and enzyme supplements and an energy source.

DETAILED DESCRIPTION - Serum free medical solution (I) comprises:

- (a) an aqueous nutrient and electrolyte solution;
- (b) a glycosaminoglycan;
- (c) a deturgescent agent;
- (d) a energy source;
- (e) a buffer system;
- (f) an antioxidant;
- (g) membrane stabilizing agents;
- (h) an antibiotic or antimycotic agent;
- (i) ATP or energy precursors;
- (j) nutrient cell supplements;
- (k) coenzymes and enzyme supplements;
- (l) nucleotide precursors;
- (m) hormonal supplements;
- (n) non-essential amino acids;
- (o) trace minerals and trace elements; and
- (p) growth factors (animal, animal recombinant, human recombinant or natural).

An INDEPENDENT CLAIM is also included for a method of treating eye tissue for use in eye surgery comprising keeping the tissue in contact with a solution (I) in the period elapsing between removing the tissue from a donor and implanting it into a recipient.

USE - The composition maintains and enhances the preservation of mammalian tissues, preferably mammalian eye tissues, before or after surgery, surgical use of a laser, or degenerative eye conditions (all claimed). In a comparative study of a serum free medical solution and standard MEM 2% FBS medium with human corneas. The results showed that after 14 and 28 days in serum free medium were able to maintain viable corneal endothelium equal in performance to corneas stored in MEM 2% FBS. The serum free medium was effective in maintaining normal corneal cell function and metabolism making it suitable as an organ culture preservation medium.

ADVANTAGE - The solution is serum free. Serum can be an agent for transmission of diseases. In a comparative study of a serum free medical solution and standard MEM 2% FBS medium with human corneas. The results showed that after 14 and 28 days in serum free medium the tissues were able to maintain viable corneal endothelium equal in performance to corneas stored in MEM 2% FBS. The serum free medium was effective in maintaining normal corneal cell function and metabolism making it suitable as an organ culture preservation medium.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: A12-V; B01-C01; B01-C04; B01-C05; B02-A; B02-C; B02-G; B02-K; B02-N;
 B02-O; B02-P; B02-S; B02-V; B03-A; B03-B; B03-D; B03-E; B03-H;
 B04-B01B; B04-C01; B04-C02; B04-C03; B04-J01; B04-L01; B04-L02;
 B04-N01; B04-N02; B05-A03; B05-B01D; B05-B01P; B05-B02C; B05-C01;
 B05-C02; B05-C05; B05-C07; B05-C08; B07-D03; B07-D04C; B10-A07;
 B10-B02; B10-B04; B10-C04E; B12-M06; **B12-M07**; B14-N03;

D09-A01

TECH

UPTX: 20000617

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Solution: (I) contains components which maintains and enhances the preservation of eye tissues at low to physiological temperatures (2-38degreesC, preferably 16-38degreesC) with a physiological pH. (a) is minimal essential medium (MEM), TC199 medium and a combination of the two. (b) is chondroitin, dermatin, heparin, heparan, or keratan sulfate, or hyaluronic acid in an amount of 0.001 mg/ml-1.0 g/ml. (c) dextran, dextran sulfate, hydroxypropylmethyl cellulose, carboxymethylcellulose, cell gum, sodium alginate, albumin, hydroxyethyl starch, hydroxyethyl cellulose, dextrose, glucose or cyclodextrin in an amount of 0.001 mg-1 g/ml. (d) is glucose, pyruvate, sucrose, fructose or dextrose and (e) is sodium bicarbonate, sodium acetate, sodium **citrate**, sodium **phosphate** or HEPES buffer, both in an amount of 0.1 mM-10 mM. (f) is L-ascorbic acid, 2-mercaptoethanol, glutathione, alpha-tocopherol, alpha-tocopherol acetate, alpha-tocopherol **phosphate** and selenium in an amount of 0.001 microM-10 mM. (g) is vitamin A, vitamin B, retinoic acid, trans-retinoic acid, retinol acetate, ethanolamine, phosphoethanolamine, transferrin, lecithin, B-sitosterol or L-alpha-phosphatidyl choline in an amount of 0.001 pg/ml-500 mg/ml. (h) is gentamycin, kanamycin, neomycin, vancomycin, obramycin, clindamycin, streptomycin, levofloxacin, penicillin, cyclosporin, amphotericin B or nystatin in an amount of 0.001 mug/ml-100 mg/ml. (i) is adenosine, inosine, adenine, flavin adenine dinucleotide, uridine 5'-triphosphate sodium, 5'-methylcytosine, beta-NAD or beta-NADP sodium in an amount of 0.001 mM-10 mM. (j) is alanyl-glutamine, glycyl-glutamine, L-amino-n-butyric acid, L-arginine, D-biotin, **betaine** hydrochloride, D-carnitine, calciferol, carotene, cholesterol, L-cystine, L-cystiene, L-glutamic acid, D-glucosamine, glucuronolactone, L-hydroxyproline, hypoxanthine, L-inositol, glycine, L-ornithine, L-proline, L-serine, myo-inositol, menadione, iacin, nicotinic acid, p-aminobenzoic acid, D-panthothenic acid, pyridoxal-5-**phosphate**, pyridoxine hydrochloride, **taurine**, thymidine, xanthine or vitamin B12 in an amount 0.001 microM-10mM. (k) is acetyl coenzyme A, cocarboxylase, coenzyme A, coenzyme Q10 or coenzyme K and (l) is 2'-deoxyadenosine, 2'-deoxycytidine hydrochloride, 2'-deoxyguanosine, 2'-deoxy-D-ribose or ribose, both in an amount of 0.001 microM-10 mM. (m) is beta-estradiol, progesterone, testosterone, cortisol, corticosterone, thyroxine, thyroid stimulating hormone or calcitonin in an amount of 0.001 pg/100 mg/ml. (n) is L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, glycine, L-proline or L-serine in an amount of 0.001 microg/ml-100 mg/ml. (o) is CuSO4.5H2O, ZnSO4.7H2O, sodium selenite, ferric **citrate**, MnSO4.H2O, NaSiO3.9H2O, molybdic acid, NH4VO3, NiSO4.6H2O, SnCl2, AgNO3, Ba(C2H3O2)2, KBr, CdCl2, CoCl2, CrCl3, NaF, GeO2, KL, RbCl or ZrOCl2.8H2O in an amount of 0.001 pg/ml-0.100 mg/ml. (p) is PDGF-BB, PDGF-AA, nerve growth factor, nerve growth factor-beta, stem cell factor, transforming growth factor-alpha, transforming growth factor-beta, vascular endothelial growth factor, beta-endothelial cell growth factor, epidermal growth factor, epithelial neutrophil activating peptide, heparin binding EGF-like growth factor, fibroblastic growth factor-acidic or basic, IGF-I, IGF-II, keratinocyte growth factor, platelet-derived endothelial cell growth factor, insulin or hepacyte growth factor in an amount 0.001 pg/ml-0.100 mg/ml.

L125 ANSWER 3 OF 3 WPIX (C) 2003 THOMSON DERWENT

AN 1997-108289 [10] WPIX

DNC C1997-034493

TI New vitamin and mineral compsn. in water soluble dry powder or aq. form - helps in e.g. cell building and cell repair and improve control of e.g. infections, heart disease, cholesterol, physiological stress and hypoglycaemia.

DC B05 D13

IN WILLIAMS, A H; WILLIAMS, E A
 PA (WILL-I) WILLIAMS A H; (WILL-I) WILLIAMS E A
 CYC 1
 PI US 5597585 A 19970128 (199710)* 5p A61K035-28
 ADT US 5597585 A US 1995-578284 19951226
 PRAI US 1995-578284 19951226
 IC ICM A61K035-28
 ICS A61K031-07; A61K031-34; A61K031-355; **A61K031-70**;
 A61K033-24; A61K033-32; A61K035-26
 AB US 5597585 A UPAB: 19970307
 Compsn. of multivitamins and minerals comprises: vitamin A (33000-40000 I.U.); vitamin C (4000-5000 mg); vitamin E (600-650 I.U.); vitamin B1 (20-200 mg); vitamin B2 (10-150 mg); vitamin B6 (30-150 mg); vitamin B12 (30-250 mg); niacin (40-70 mg); niacinamide (20-50 mg); pantothenic acid (20-500 mg); folic acid (0.3-0.6 mg); biotin (30- 100 mg); choline (400-725 mg); inositol (40-100 mg); **DL-methionine** (160-1000 mg); magnesium (300-420 mg); potassium (100-420 mg); manganese (5-10 mg); zinc (15-30 mg); chromium (130-200 mg); selenium (200-250 mg); **betaine** (120-130 mg); L-cysteine (660- 1000 mg); thymus concentrate (30-100 mg); and spleen concentrate (30-100 mg). The compsn. opt. comprises 50-100 mg ethylenediamine tetraacetic acid and is pref. in the form of a dry water soluble powder, or in aq. form.
 USE - The dry compsn. may be dissolved in water to provide a health drink of vitamins and minerals. The aq. compsns. can help in e.g. cell building and cell repair, and improve control of infections, heart disease, cholesterol, physiological stress, hypoglycaemia, adrenal weakness, arthritis, menopause, candidiasis, premenstrual syndrome, hypertension, osteoporosis, anaemia and cataracts.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: B03-A; B03-B; B03-C; B03-D; B03-E; B03-F; B03-H; B05-A01A; B05-A01B; B05-A03A; B07-D04C; B10-B01B; B10-B02D; B10-B02J; B10-E04C; B14-E11; D03-H01T2

=> d his

(FILE 'HOME' ENTERED AT 12:22:11 ON 10 MAR 2003)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 12:22:26 ON 10 MAR 2003
 ACT KWON770/A

```

-----
L1 (      1)SEA FILE=REGISTRY ABB=ON  PLU=ON  BETAINE/CN
L2 (      3)SEA FILE=REGISTRY ABB=ON  PLU=ON  C5H12NO2/MF AND N N N TRIMETH
L3 (      1)SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT (LABELED OR D/ELS)
L4 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  (L1 OR L3)
L5 (      1)SEA FILE=REGISTRY ABB=ON  PLU=ON  SILIBININ/CN
L6 (      7)SEA FILE=REGISTRY ABB=ON  PLU=ON  (SILYMARIN/CN OR "SILYMARIN I
L7 (      6)SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 NOT C4H6O4
L8 (      6)SEA FILE=REGISTRY ABB=ON  PLU=ON  (L5 OR L7)
L9 (      3)SEA FILE=REGISTRY ABB=ON  PLU=ON  (D-GLUCOSE OR L-GLUCOSE OR DL
L10 (     14)SEA FILE=REGISTRY ABB=ON  PLU=ON  (D-FRUCTOSE OR L-FRUCTOSE OR
L11 (      8)SEA FILE=REGISTRY ABB=ON  PLU=ON  (GLYCEROL OR LIPOIC ACID OR C
L12 (      3)SEA FILE=REGISTRY ABB=ON  PLU=ON  (D-METHIONINE OR L-METHIONINE
L13 (      1)SEA FILE=REGISTRY ABB=ON  PLU=ON  TOCOPHEROL/CN
L14 (      1)SEA FILE=REGISTRY ABB=ON  PLU=ON  VITAMIN E/CN
L15 (      9)SEA FILE=REGISTRY ABB=ON  PLU=ON  (SODIUM OR POTASSIUM OR CHLOR
L16 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("SODIUM, ION (NA1+)"/CN OR "
L17 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("POTASSIUM, ION (K1+)"/CN OR
L18 (      4)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("CHLORINE, ION (CL1+)"/CN OR
L19 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("PHOSPHORUS, ION (P1+)"/CN O

```

```

L20 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("MAGNESIUM, ION (MG1+)")/CN O
L21 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("ZINC, ION (ZN1+)")/CN OR "ZI
L22 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("CALCIUM, ION (CA1+)")/CN OR
L23 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("IRON, ION (FE1+)")/CN OR "IR
L24 (      2)SEA FILE=REGISTRY ABB=ON  PLU=ON  ("COPPER, ION (CU1+)")/CN OR "
L25 (    4700)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4 OR L8
L26 (    637)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (SILYMARIN/BI OR SILYMARINE/BI
L27 (      0)SEA FILE=HCAPLUS ABB=ON  PLU=ON  SILY MARIN?
L28 (   15024)SEA FILE=HCAPLUS ABB=ON  PLU=ON  BETAINE
L29 (    115)SEA FILE=HCAPLUS ABB=ON  PLU=ON  FLAVONOLIGNAN?
L30 (     42)SEA FILE=HCAPLUS ABB=ON  PLU=ON  "LIGNANS (L) FLAVONO-"/CT
L31 (    2724)SEA FILE=HCAPLUS ABB=ON  PLU=ON  LIGNANS+NT/CT
L32 (    320)SEA FILE=HCAPLUS ABB=ON  PLU=ON  LIGNAN(L) FLAVON?
L33 (   19242)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L25 OR L26 OR L27 OR L28 OR L
L34 (    794)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND CARBOHYDRATE?/SC, SX, CW
L35 (    316)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND (?OLIGOSACCHARIDE? OR
L36 (    399)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND ?SACCHARIDE?
L37 (    324)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND L9
L38 (    627)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND GLUCOSE
L39 (    322)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND L10
L40 (    483)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND (FRUCTOSE OR GALACTOSE
L41 (   1795)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L34 OR L35 OR L36 OR L37 OR L
L42 (    359)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41 AND L11
L43 (     90)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41 AND L12
L44 (     43)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41 AND (L13 OR L14)
L45 (    651)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41 AND (GLYCEROL OR GLYCERIN#
L46 (    687)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L42 OR L43 OR L44 OR L45)
L47 (     96)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND (L15 OR L16 OR L17 OR
L48 (     46)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND MINERAL
L49 (    450)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND (NA OR K OR CL OR P OR
L50 (    454)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L47 OR L48 OR L49)

```

```

-----
L51      30 S L50 AND (DEHYDRAT? OR REHYDRAT? OR HYPOHYDRAT? OR HYDRAT?)
L52     12 S L51 AND (FOOD? OR FEED? OR PHARMACEUT? OR PHARMACOL? OR COSME
      E DEHYDRATION/CT
L53    2464 S E19
      E E19+ALL
      E E2+ALL
L54    1011 S E2+NT
      E E12+ALL
L55   20797 S E2, E3, E1+NT
L56     10 S L51 AND L53-L55
L57     18 S L52, L56
      SEL DN AN 1 L57
L58     1 S L57 AND E1-E3

```

FILE 'REGISTRY' ENTERED AT 12:31:21 ON 10 MAR 2003

```

L59     1 S 6915-15-7

```

FILE 'HCAPLUS' ENTERED AT 12:31:38 ON 10 MAR 2003

```

L60     24 S L50 AND L59
L61     22 S L60 NOT L51
L62      2 S L60 NOT L61
L63      1 S L62 AND REHYDRAT?
L64      1 S L58, L63
L65     74 S L50 AND (NUTRI? OR FOOD? OR FEED?)/SC, SX, CW
L66      1 S L65 AND L53-L55
L67     19 S L50 AND (BEVERAG? OR JUICE?)
      E BEVERAGE/CT
      E E6+ALL
L68   51873 S E2+NT
L69   44930 S E82+NT
      E E82+ALL

```

E E9 ALL
 E DAIRY/CT
 E E12+ALL
 L70 49688 S E3+NT
 E FOOD/CT
 L71 50568 S E3
 E NUTRITION/CT
 E E9+ALL
 L72 78148 S E4,E3+NT
 L73 309996 S E26+NT OR E28+NT OR E35+NT
 L74 131 S L50 AND L68-L73
 L75 160 S L65,L67,L74 NOT L51
 L76 124 S L75 NOT COSMETIC?/SC
 L77 35 S L76 AND (ARTHRIT? OR NUTRI? OR DIETARY? OR MEDICINAL OR MATRI
 SEL' DN AN 2 3 4 5 17 18 19 24 25
 L78 9 S E1-E27
 L79 10 S L58,L64,L66,L78 AND L51-L58,L60-L78
 E VERLAAN G/AU
 L80 4 S E3,E4
 E HAGEMAN R/AU
 L81 33 S E3,E6,E10-E13
 E SMEETS R/AU
 L82 23 S E3,E8,E9,E15,E16
 E LODEWIJK/AU
 E SMEETS L/AU
 L83 52 S L80-L82
 L84 4 S L83 AND L50,L59
 E NUTRICIA/PA,CS
 L85 63 S E3-E15
 L86 63 S NUTRICIA?/PA,CS
 L87 4 S L85,L86 AND L50,L59
 L88 11 S L79,L84,L87
 L89 91 S L83,L85,L86 NOT L88

FILE 'REGISTRY' ENTERED AT 13:02:50 ON 10 MAR 2003

L90 25 S (BETAINE OR SILYMARIN?)/CN
 L91 15 S L90 AND 1/NC
 L92 1 S C5H12NO2/MF AND N N N TRIMETHYL NOT (LABELED OR D/ELS)

FILE 'HCAPLUS' ENTERED AT 13:03:57 ON 10 MAR 2003

L93 16475 S L91 OR L92 OR BETAINE OR SILYMARIN? OR SILIBIN?
 L94 385 S FLAVONOLIGNAN? OR LIGNAN?(L) FLAVO?
 L95 16776 S L93,L94
 L96 670 S L95 AND (?SACCHARIDE? OR CARBOHYDRATE?)

FILE 'REGISTRY' ENTERED AT 13:05:49 ON 10 MAR 2003

L97 14 S (GLUCOSE OR FRUCTOSE OR GALACTOSE OR MANNOSE OR RIBOSE OR INO

FILE 'HCAPLUS' ENTERED AT 13:06:17 ON 10 MAR 2003

L98 482 S L97 AND L95
 L99 940 S (?GLUCOSE? OR ?FRUCTOSE? OR ?GALACTOSE? OR ?MANNOSE? OR ?RIBO
 L100 1431 S L96,L98,L99

FILE 'REGISTRY' ENTERED AT 13:08:42 ON 10 MAR 2003

L101 10 S (GLYCEROL OR CAFFEINE OR LIPOIC ACID OR CITRIC ACID OR PHOSPH

FILE 'HCAPLUS' ENTERED AT 13:08:52 ON 10 MAR 2003

L102 397 S L101 AND L100
 L103 540 S L100 AND (GLYCEROL OR GLYCERIN# OR PROPANETRIOL OR CAFFEINE O
 L104 569 S L102,L103

FILE 'REGISTRY' ENTERED AT 13:10:13 ON 10 MAR 2003

L105 1 S VITAMIN "E"/CN

FILE 'HCAPLUS' ENTERED AT 13:10:42 ON 10 MAR 2003

L106 55 S L104 AND (L105 OR VITAMIN "E" OR ?TOCOPHER?)
L107 569 S L104,L106
L108 12 S L107 AND L53-L55
SEL DN AN 1 11
L109 2 S E1-E6
L110 12 S L88,L109
L111 11 S L110 AND (FOOD? OR FEED? OR BEVERAG? OR NUTRI? OR ?DRINK? OR
L112 1 S L110 NOT L111
L113 12 S L110-L112
L114 12 S L113 AND (VITAMIN? OR MINERAL? OR SODIUM OR POTASSIUM OR CHLO

FILE 'HCAPLUS' ENTERED AT 13:14:56 ON 10 MAR 2003

FILE 'WPIX' ENTERED AT 13:15:41 ON 10 MAR 2003

E WO2002058792/PN
L115 1 S E3
L116 12639 S A61K031-70/IC,ICM,ICS
L117 47 S L116 AND (?FLAVONOLIGNAN? OR ?FLAVONO?(L)?LIGNAN? OR BETAIN?
E SILYMARIN/DCN
E E4+ALL
L118 15 S E2
E SILYBIN/DCN
E E3+ALL
L119 10 S L116 AND (L118 OR ?SILYMARIN? OR ?SILIBIN? OR ?SILYBIN?)
L120 50 S L117,L119
L121 17 S L120 AND (GLYCEROL OR GLYCERIN? OR PROPANETRIOL OR (LIPOIC OR
L122 3 S R023/M0,M1,M2,M3,M4,M5,M6 AND L121
L123 14 S L120 AND (B05-A? OR C05-A? OR B05-C? OR C05-C?)/MC
L124 2 S L120 AND (B12-M07 OR C12-M07)/MC
L125 3 S L122,L124,L115
L126 20 S L121,L123 NOT L125

FILE 'WPIX' ENTERED AT 13:27:12 ON 10 MAR 2003